Novo weight loss drug trial shows improvement in fatty liver disease
Novo Nordisk said Friday that its weight-loss drug achieved the primary goal of a late-stage study in patients with fatty liver disease, reducing scarring of the organ without worsening the condition.
POPULAR POSTS
Thousands left without power in Washington State
November 21, 2024
Eight times as many children will face extreme heatwaves in 2050
November 21, 2024
Elton John’s Tammy Faye to close on Broadway
November 21, 2024
LIVE STREAM